Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/4224
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
PERFOROMIST (Solution)
|
| dailymed-instance:activeIng... | |
| dailymed-instance:boxedWarn... |
WARNING: INCREASED RISK OF ASTHMA-RELATED DEATH: Long-acting beta-adrenergic agonists may increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta-adrenergic agonist), the active ingredient in PERFOROMIST Inhalation Solution. [see WARNINGS AND PRECAUTIONS (5.1)]
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
formoterol fumarate dihydrate
|
| dailymed-instance:fullName |
PERFOROMIST (Solution)
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
PERFOROMIST
|